Refine your search
Collections
Co-Authors
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Manjula, B.
- Novel Therapies to Combat HIV: A Review
Abstract Views :326 |
PDF Views:0
Authors
Affiliations
1 P.G. Department of Pharmacology, Shree Siddaganga College of Pharmacy, Tumkur-572102, IN
1 P.G. Department of Pharmacology, Shree Siddaganga College of Pharmacy, Tumkur-572102, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 1, No 1 (2009), Pagination: 1-6Abstract
No Abstract.
References
- Myron CS, Nick H, Jay LA, Kevin DC, Joep Lange. The spread, treatment and prevention of HIV-1. J Clin Invest.2008:1244-54.
- Zheng NN, Kiviat NB, Sow PS, Hawes SE, Wilson A, Diallo-Agne H. Comparison of human immunodeficiency virus (HIV)-specific T-cell responses in HIV-1 and HIV-2-infected individuals in senegal. J Virol. 2004:13934–42.
- Jose MC, Michael F, Daniel PC, Paul MJ, William OC. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1. 2006: 3289– 96
- Qi G, Hsu-Tso H, Ira D, Li F, Nannan Z, Jacques F,et al. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J virol. 2003:10528–36.
- Hsu-Tso H, Li F, Beata NS, Brian MA, Chang-Ben L, Gregory Y,et al. Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events. J Virol. 2006:4017–25.
- Phogat S, Wyatt RT, Karlsson HGB. Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets. J Intern Med. 2007: 26–43.
- John MP, Robert DW. The entry of entry inhibitors. A fusion of science and medicine. 2003: 19.
- Tonie C, Jabulani N, Mia C, Dragana O, Thomas K, William OC, et al. The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol. 2003: 4449–56.
- Rachel B, Johanne M. Association between disruption of CD4 receptor dimerization and increased human immunodeficiency virus type 1 entry. Retrovirology. 2006: 31.
- Won-TC, Shaomin T, Chang-Zhi D, Santosh K,Dongxiang L, Navid M, et al. Unique ligand binding sites on CXCR4 probed by a chemical biology approach. J Virol. 2005: 15398–404.
- Hans SP, Sarah S, Bruce DJ, Jeffrey JM. New approaches in the treatment of HIV/AIDS –focus on maraviroc and other CCR5 antagonists. Therapeutics and Clinical Risk Management. 2008: 473–85.
- George, Frederic B, Josephine R, Robert DW, James HA. Identification of gp120 binding sites on CXCR4 by using CD4-independent human immunodeficiency virus type 2 Envelope Proteins. J Virol. 2003: 931–42.
- Chih-chin H, Min T, Mei-Yun Z, Shahzad M, Elizabeth M, Robyn SL, et al. Structure of a V3-containing HIV-1 gp120 core. Science. 2005: 1025-28.
- Quan-en Y, Andrew SG, Joseph AW, Paula RE, Weimin Z, Michael CJ, et al. Discovery of small molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4. J Virol, 2005: 6122–33.
- Emily PJ, James DP, David K. Efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus. J Virol, 2005: 4347–56.
- Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet. 2005: 549–55.
- Jacqueline RD, Stephen GA, Navid A, John ML, Phoebe HE, Matthew S, et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope_coreceptor affinity, receptor density, and fusion kinetics. PNAS. 2002: 16249–54.
- Lederman MM, Veazey RS, Offord R, Mosier DE, Dufour J, Mefford M, et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science. 2004: 485–7.
- Xing-Quan Z, Meredith S, Michael F, Robert ST. Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (t-20).Science. 2006: 2231–3.
- Christina KMR, Miriam N, Scott KG, Paul K. Enfuvirtide antiretroviral therapy in HIV-1 infection. Therapeutics and Clinical Risk Management. 2008: 433–9.
- Ping Z, William C, Olson, Kenneth H. Structural flexibility and functional valence of CD4-IgG2 (PRO 542): potential for cross-linking human immunodeficiency virus type 1 envelope spikes. J Virol. 2001: 6682–6.
- Jeffrey MJ, Robert JI, Israel L, Nancy AO, Linda SV, Melanie B, et al. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother. 2004: 423–9.
- Navid M, Ana LP, Kumar S, Jason MC, Jason JC, Judith LL, et al. Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155. J Virol. 2004: 3742–52.
- Zhihai S, Navid M, Jason MC, Jason JC, Jeffrey CK, Arne S, Ngoc P, et al. Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc Natl Acad Sci U S A. 2004: 5036–41.
- Michelle M, Jing L, Steven DG, Rainer Z, Danie KR. Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations. J of Clinical Microbiology. 2006: 3384–7.
- Hans PS, Sarah S, Bruce JD, Jeffrey MJ. New approaches in the treatment of HIV/AIDS – focus on maraviroc and other CCR5 antagonists. Ther Clin Risk Manag. 2008: 473–85.
- Cecile LT, Françoise Gl, Christopher K, Yongbiao G, Ting-Chao C, Bahige MB, et al. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob Agents Chemother. 2002: 1336–9.
- Surendiran A. Entry Inhibitor - Maraviroc in HIV treatment. Jipmer. 2008: 3-4.
- Julie MS, Cecile T, Serena X, Lisa W, Nicole W, Waldemar G, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2005: 4911-9.
- Alonso H, Bruce G, Olga L, Nhut L, Douty B, Anthony D, et al. Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro. Antimicrob Agents Chemother. 2007: 2489–96.
- Christina MRK, Miriam N, Scott GK, Paul K. Enfuvirtide antiretroviral therapy in HIV-1 infection. Therapeutics and Clinical Risk Management. 2008: 433–9.
- Hartmut S, Charlotte K, Nele P, Antje B, Guido K, Christian H, et al. Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings. Antimicrob Agents Chemother. 2006: 667–73
- Michelle M, Jing L, Steven DG, Rainer Z, Daniel KR. Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations. J of clinical microbiology. 2006: 3384–7.
- Metabolomics - An Exciting New Field Within the "OMICS" Sciences
Abstract Views :204 |
PDF Views:2
Authors
Affiliations
1 Department of Pharmacology, Sree Siddaganga College of Pharmacology, B.H. Road, Tumkur-572102, Karnataka, IN
2 Dept. of Pharmacology, PES College of Pharmacy, Bangalore-50, Karnataka, IN
1 Department of Pharmacology, Sree Siddaganga College of Pharmacology, B.H. Road, Tumkur-572102, Karnataka, IN
2 Dept. of Pharmacology, PES College of Pharmacy, Bangalore-50, Karnataka, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 2, No 6 (2010), Pagination: 363-369Abstract
Metabolomics is a newly emerging Science which can be seen as an advanced, specialized form of Analytical Biochemistry. This technology is centered around the detection of small molecules and, by definition, excludes the organic biopolymers such as proteins and fatty acids. Important small metabolites include amino and other organic acids, sugars, volatile metabolites and most of the diverse secondary metabolites found in plants such as alkaloids, phenolic components and coloured metabolites such as carotenoids and anthocyanins. Key to any metabolomics approach is the aim to gain the broadest overview possible of the biochemical composition of complex biological samples in just one or a small number of analyses. Liquid or gas chromatography (LC or GC) are usually used to separate the individual components in complex organic extracts after which Mass Spectrometry (MS) is employed to detect the metabolites present. Alternatively, Nuclear Magnetic Resonance (NMR) may be used. Characteristic of this technology is the large scale nature of the analyses performed - involving not only the semi-automated production of a large amount of complex data per analysis but also performing these analyses sequentially on large numbers of samples. Highly complex data matrices are obtained - often of many Gigabytes. Consequently, metabolomics analyses can only be performed when all the necessary computing and bioinformatics tools are in place to allow automated data storage and efficient non-labour intensive data analysis. Metabolomics is usually used either for 'fingerprinting' samples to perform comparative analyses to detect differences of for 'profiling' where individual differential metabolites are identified for further analysis.References
- Simone R. Metabolomics reviewed: A new "Omics" platform technology for systems biology and implications for natural products research. J Nat Prod 2005; 12: 1813-20.
- Nordstroem A, O'Maille G, Qin C, Siuzdak G. "Nonlinear data alignment for UPLC-MS and HPLC-MS based metabolomics: quantitative analysis of endogenous and exogenous metabolites in human serum". Anal. Chem 2006; 78: 3289-95.
- Gibney MJ, Walsh M, Brennan L, Roche HM, German B, van Ommen B. "Metabolomics in human nutrition: opportunities and challenges". Am. J. Clin. Nutr 2005; 82: 497-503.
- Gomase VS, Changbhale SS, Patil SA, Kale KV. "Metabolomics". Current Drug Metabolism 2008; 9: 89-98.
- Lindon JC, Holmes E and Nicholson JK. Metabonomics in pharmaceutical R & D. Journal 2007; 274: 1140-51.
- D.S. Wishart. Current progress in computational metabolomics. Bioinformatics 2007; 8: 279-93.
- Fiehn O. Comp. Funct. Genom. 2 (155- 168) 2001, Plant Mol. Biol. 48 (155- 171) 2002.
- Crockford DJ, Maher AD, Ahmadi KR et al. "1H NMR and UPLCMS (E) statistical heterospectroscopy: characterization of drug metabolites (xenometabolome) in epidemiological studies". Anal. Chem 2008; 80: 6835-44.
- Harris WS, Schacky C. The omega-3 index: a new risk factor for death from coronary heart disease. Prev Med 2004; 39: 212-220.
- Scholz M, Gatzek S, Sterling A et al. Metabolite fingerprinting: detecting biological features by independent component analysis. Bioinformatics 2004; 20: 2447-54.
- Sweetlove LJ, Fernie AR. Regulation of metabolic networks: understanding metabolic complexity in the systems biology era. New Phytol 2005; 168: 9-24.
- Sumner LW, Mendes P, Dixon RA. Large-scale phytochemistry in the functional genomics era. Phytochemistry 2003; 63: 817-36.
- Schauer N, Steinhauser D, Strelkov S et al. "GC-MS libraries for the rapid identification of metabolites in complex biological samples". FEBS Lett 2005; 6: 1332-7.
- David SW. Current progress in computational metabolomics 2007.
- Greef J, Tas AC, Bouwman J, Ten MC, Schreurs WHP. Evaluation of field-desorption and fast atom bombardment mass spectrometric profiles by pattern-recognition techniques. Anal. Chim. Acta 1983; 150: 4552.
- Dunn WB, Ellis DI. Metabolomics: current analytical platforms and methodologies. Trends in Analytical Chemistry 2005; 4: 285-94.
- Buchholz A, Takors R, Wandrey C. Quantification of intracellular metabolites in Escherichia coli K12 using liquid chromatographic electrospray ionization tandem mass spectrometric techniques. Anal Biochem 2005; 295: 129-37.
- Lenz EM, Bright J, Knight R, Wilson ID, Major H. Cyclosporin A induced changes in endogenous metabolites in rat urine: A metabonomic investigation using high field 1H NMR spectroscopy, HPLC-TOF/MS and chemometrics. J Pharm Biomed Anal 2004; 35: 599-608.
- Lenz EM, Bright J, Knight R, Wilson ID, Major H. A metabonomic investigation of the biochemical effects of mercuric chloride in the rat using 1H NMR and HPLC-TOF/MS: Time dependent changes in the urinary profile of endogenous metabolites as a result of nephrotoxicity. Analyst 2004; 129: 535-41.
- Plumb RS, Stumpf CL, Granger JH, Castro-Perez J, Haselden JN, Dear GJ. Use of liquid chromatography/time-of-flight mass spectrometry and multivariate statistical analysis shows promise for the detection of drug metabolites in biological fluids. Rapid Commun Mass Spectrom 2003; 17: 2632-8.
- Robertson DG. "Metabonomics in toxicology: a review". Toxicol. Sci. 2005; 2: 809-22.
- Saghatelian A et al. "Assignment of endogenous substrates to enzymes by global metabolite profiling." Biochemistry 2004; 45: 14332-9.
- Chiang KP et al. "An enzyme that regulates ether lipid signaling pathways in cancer annotated by multidimensional profiling." Chem. Biol 2006; 10: 1041-50.
- Nicholson JK, Lindon JC, Holmes E. "'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data". Xenobiotica 1999; 11: 1181-9.
- Ellis DI and Goodacre R. Metabolic fingerprinting in disease diagnosis: biomedical applications of infrared and Raman spectroscopy. Analyst 2006; 131: 875-85.
- Anti-Obesity Activity of Ethanolic Extract of Moringa oleifera Seeds in Experimental Animals
Abstract Views :368 |
PDF Views:2
Authors
Affiliations
1 Department of Pharmacocology, Sree Siddaganga College of Pharmacy, Tumkur-572 102, IN
1 Department of Pharmacocology, Sree Siddaganga College of Pharmacy, Tumkur-572 102, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 3, No 6 (2011), Pagination: 318-328Abstract
Background and Objectives: Obesity is closely associated with life-style-related disorders such as arteriosclerosis, hyperlipidemia, hypertension and type-2 diabetes mellitus. Moringa oleifera Lam. Seeds were proved scientifically for the treatment of lifestyle related disorders. Present study was performed to clarify whether an M. oleifera Lam. Seeds ethanol extract (MOE) prevent high-fat diet-induced obesity in mice fed for nine weeks.
Methods: We have performed two in vivo experiments such as high-fat diet-induced obesity mice model and lipid emulsion tolerance test in normal rats. In high-fat diet-induced obesity mice model, female Swiss mice were fed a high fat diet (HFD; 40% fat) with or without 1 or 2 % of MOE or 0.012% orlistat for nine weeks. In lipid emulsion tolerance test male Wistar rats were orally administered, lipid emulsion with or without 500 mg/kg or 1000 mg/kg of MOE and the plasma triglycerides were measured from 0.5 to 5 h.
Results: Consumption of HFD containing MOE to mice for nine weeks exhibited significant reduction in lipid parameters, body weight, parametrial adipose tissue weight, liver TG and different organs weight compared to HFD fed control. Whereas, improvement in insulin resistance induced by HFD alone group. Furthermore, consumption of a HFD containing 1 or 2 % of MOE significantly increased the fecal content and fecal triglyceride compared with the HFD group. Pre-treatment with MOE inhibited the elevated plasma triglyceride level after the oral administration of the lipid emulsion to rats. In other words, administration of MOE improves lipid tolerance in rats.
Conclusion: Observed anti-obesity activity of MOE in experimental animals may be partly mediated through delaying the intestinal absorption of dietary fat by inhibiting pancreatic lipase activity as evident from similar profile of activity as that of orlistat.
Keywords
MOE, High Fat Diet, Insulin Tolerance, Lipid Parameter, Lipid Emulsion, Fecal TG.References
- Leonhardt M, Hrupka B, Langhans W. New approaches in the pharmacological treatment of obesity. Eur J Nutr. 38; 1999: 1-13.
- Hill JO, Melanson EL, Wyatt HT. Dietary fat intake and regulation of energy balance: implications for obesity. J Nutr. 130; 2000: 284S-8S.
- Leslie WS et al. Weight management: a comparison of existing dietary approaches in a work-site setting. Endocrine Rev. 26; 2002: 1469-75.
- Verger R. Pancreatic lipase. Edited by: Borgstrom B, Brockman HL. Elsevier, Amsterdam, 1984: 83-105.
- Bray and Greenway. Current and potential drugs for treatment of obesity. Endocrine Rev. 20; 1999: 805-75.
- Sarah HB, Robert B, Clifford JB. High body mass index for age among US children and adolescents. Asian Nat Prod Res. 4; 2000: 321-7.
- Guevara AP, Vargas C, Sakurai H, Fujiwara Y, Hashimoto K, Maoka T et al. An antitumor promoter from Moringa oleifera. Mutat Res. 440; 1999: 181-8.
- Makkar PS and Becker K. Nutrients and anti-quality factors in different morphological parts of the Moringa oleifera tree. Journal of Agricultural Science. 128; 1997: 311-22.
- Makkar HP and Becker K. Nutritional value and anti-nutritional components of whole and extracted Moringa oleifera leaves. Anim. Feed Sci. Technol. 63; 1996: 211-28.
- Li-Kun H, Bao-Jun X, Yoshiyuki K, Yi-nan Z and Hiromichi O. Platycodi radix affects lipid metabolism in mice with high fat diet-induced obesity. J Nutr. 130; 2000: 2760-4.
- Ukwuani AN, Abukakar MG, Shehu RA and Hassan LG. Anti obesity effects of pulp extract Tamarindus indica in albino rat. Asian Journal of Biochemistry. 3; 2008: 221-7.
- Nair S, Feng, Machender RK, Xiaoping Y and Jun R. Chromium alleviate glucose intolerance, insulin resistance, and hepatic ER stress in obese mice. Obesity. 16; 2008: 1331-7.
- Li-Kun H, Yi-Nan Z, Masayuki Y, Hiromichi O and Yoshiyuki K. Anti-obesity effects of chikusetsusaponins isolated from Panax japonicus rhizomes. BMC Complementary and Alternative Medicine. 5; 2005: 1-10.
- Friedewald WT, Levy RI and Fredrickson DS. Estimation of low-density lipoprotein cholesterol in plasma, without use of the preparative centrifuge. Clinical Chemistry. 18; 1972: 499-501.
- Wencong L, Yinan Z, Likun H, HaiminW, Masato S, Mingsong L et al. Saponins (Ginsenosides) from stems and leaves of Panax quinquefolium prevented high-fat diet-induced obesity in mice. Phytomedicine. 15; 2008: 1140–5.
- Gurpreet K, Kulkarni SK. Antiobesity effect of a polyherbal formulation, ob-200g in female rats fed on cafeteria and atherogenic diets. Indian Journal of Pharmacology. 32; 2000: 294-9.
- Mingfang L and Bernard MY. Pharmacotherapy for obesity. Br J Clin Pharmacol. 6; 2007: 804-10.
- Faizi S, Siddiqui BS, Saleem R, Siddiqui S, Aftab K, Gilani AH. Fully acetylated carbamate and hypotensive thiocarbamate glycosides from Moringa oleifera. Phytochemistry. 38; 1998: 957-63.
- Lalas S, Tsaknis J. Extraction and identification of natural antioxidants from the seeds of Moringa oleifera tree variety of Malavi. J Am Oil Chem Soc. 79; 2002: 677-83.
- Randle et al. The glucose fatty-acid cycle: Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1; 1963: 785-9.
- Belfiore F. Insulin resistance in obesity: Metabolic mechanisms and measurement methods. Mol Gen Metab. 65; 1998: 121-8.
- Srinivasan K, Patole PS, Kaul CL, Ramarao P. Reversal of glucose intolerance by pioglitazone in high-fat diet fed rats. Methods Find Exp Clin Pharmacol. 26; 2004: 327-33.
- Shafrir E et al. Contribution to the understanding of diabetes by study of its etiopathology in animal models. Diabetes Mellitus. 5; 2003: 231-55.
- Newsholme, EA and Crabtree B. Biochem. Soc. Symp. 41; 1976: 61-110.
- Kalopissis et al. Very-low-density-lipoprotein secretion by isolated hepatocytes of fat-fed rats. Biochem J. 198; 1981: 373-7.
- Sambaiah MR and Satyanarayana MN. J Biosci. 12; 1987: 143.
- Montani et al. Ectopic fat storage in key cardiovascular organs. Int J Biochem Cell Biol. 35; 2003: 807-25.